SAIC Motor’s Hengxu Capital helped allosteric drug developer Nutshell Therapeutics close a $40m round while cancer therapy developer Impact Therapeutics secured series D1 funding.
Funding
China-based allosteric drug developer Nutshell Therapeutics has completed a $40m series A-plus round today featuring carmaker SAIC Motor’s Hengxu Capital fund-of-funds vehicle, DealStreetAsia reported today. Genesis Capital led the round, which included Source Code Capital, Kunlun Capital, Matrix Partners China and Northern Light Venture Capital.
China-headquartered oncology therapy developer Impact Therapeutics closed a series D1 round of undisclosed size yesterday featuring real estate developer Yuexiu Property; C&D Emerging Capital, a vehicle for supply chain services firm Xiamen C&D; and…
